Who Buys Tofacitinib from India — 213 Importers Behind a $4.0M Market

The 213 buyers of Tofacitinib from India can be categorized into several segments:

1. Pharmaceutical Distributors: Entities that purchase Tofacitinib in bulk for distribution to various healthcare providers. For instance, TARO PHARMACEUTICALS INC. in Canada, accounting for approximately $2.95 million across multiple entries, likely operates as a distributor, supplying the drug to pharmacies and hospitals. Distributors typically place large, periodic orders to maintain a steady supply chain.

2. Hospital Groups: Organizations managing multiple healthcare facilities that procure medications for inpatient and outpatient care. While specific hospital groups are not explicitly listed among the top buyers, entities like HARLEYS LIMITED in Kenya ($0.03 million) may serve hospital networks. These buyers often order based on patient demand and formulary requirements, leading to consistent purchasing patterns.

3. Retail Pharmacy Chains: Companies operating multiple pharmacy outlets that purchase Tofacitinib to stock their shelves. Although not directly identified in the top 10 buyers, such chains would typically place regular orders to meet consumer demand.

4. Government Procurement Agencies: National or international bodies responsible for acquiring medications for public health programs. Entities like NILA JAMAL ENTERPRISE in Malaysia ($0.16 million) and VMG HEALTHCARE PRODUCTS GUATEMALA S in Guatemala ($0.16 million) may be involved in government tenders. These agencies often procure large quantities through competitive bidding processes, resulting in substantial, infrequent orders.

5. Re-exporters: Companies that import Tofacitinib with the intent to export it to other markets. For example, ATLAS TRADING COMPANY in Iraq ($0.08 million) might engage in such activities. Re-exporters' purchasing behavior is influenced by demand fluctuations in target markets, leading to variable order sizes and frequencies.

6. Contract Manufacturers: Firms that import Tofacitinib as an active pharmaceutical ingredient (API) for formulation into finished products. While not explicitly listed among the top buyers, such manufacturers typically order based on production schedules and client demands, resulting in bulk, periodic purchases.

For the top five importing countries of Tofacitinib from India, the import regulations are as follows:

The demand for Tofacitinib in importing countries is influenced by several factors:

1. Disease Prevalence: Tofacitinib is primarily used to treat rheumatoid arthritis and other autoimmune conditions. Countries with higher prevalence rates of these diseases exhibit increased demand for effective treatments. For example, the prevalence of rheumatoid arthritis in Canada is approximately 0.9%, contributing to substantial demand for Tofacitinib.

2. Government Healthcare Programs: National health initiatives that subsidize or cover the cost of medications enhance accessibility. In Malaysia, the Ministry of Health provides subsidized treatment for chronic diseases, including rheumatoid arthritis, thereby increasing the demand for medications like Tofacitinib.

3. Universal Health Coverage Expansion: Countries expanding their health coverage to include a broader population base see a rise in pharmaceutical demand. Guatemala's efforts to improve healthcare access have led to increased procurement of essential medicines.

4. WHO Essential Medicines List Procurement: Inclusion of medications in the WHO Essential Medicines List encourages countries to procure these drugs for public health programs. While Tofacitinib is not currently listed, its therapeutic class is recognized, influencing procurement decisions.

5. Tender-Based Purchasing: Many countries utilize tender systems for bulk purchasing of pharmaceuticals, ensuring cost-effectiveness and consistent supply. Iraq and Guatemala, for instance, often engage in tender-based procurement for medications, impacting the volume and frequency of Tofacitinib imports.

With 213 buyers across 67 countries, the global demand for Tofacitinib reflects a combination of disease burden, healthcare policies, and procurement strategies, presenting significant market opportunities for suppliers.

The 213 buyers of Tofacitinib from India can be categorized into several segments:

1. Pharmaceutical Distributors: Entities that purchase Tofacitinib in bulk for distribution to various healthcare providers. For instance, TARO PHARMACEUTICALS INC. in Canada, accounting for approximately $2.95 million across multiple entries, likely operates as a distributor, supplying the drug to pharmacies and hospitals. Distributors typically place large, periodic orders to maintain a steady supply chain.

2. Hospital Groups: Organizations managing multiple healthcare facilities that procure medications for inpatient and outpatient care. While specific hospital groups are not explicitly listed among the top buyers, entities like HARLEYS LIMITED in Kenya ($0.03 million) may serve hospital networks. These buyers often order based on patient demand and formulary requirements, leading to consistent purchasing patterns.

3. Retail Pharmacy Chains: Companies operating multiple pharmacy outlets that purchase Tofacitinib to stock their shelves. Although not directly identified in the top 10 buyers, such chains would typically place regular orders to meet consumer demand.

4. Government Procurement Agencies: National or international bodies responsible for acquiring medications for public health programs. Entities like NILA JAMAL ENTERPRISE in Malaysia ($0.16 million) and VMG HEALTHCARE PRODUCTS GUATEMALA S in Guatemala ($0.16 million) may be involved in government tenders. These agencies often procure large quantities through competitive bidding processes, resulting in substantial, infrequent orders.

5. Re-exporters: Companies that import Tofacitinib with the intent to export it to other markets. For example, ATLAS TRADING COMPANY in Iraq ($0.08 million) might engage in such activities. Re-exporters' purchasing behavior is influenced by demand fluctuations in target markets, leading to variable order sizes and frequencies.

6. Contract Manufacturers: Firms that import Tofacitinib as an active pharmaceutical ingredient (API) for formulation into finished products. While not explicitly listed among the top buyers, such manufacturers typically order based on production schedules and client demands, resulting in bulk, periodic purchases.

For the top five importing countries of Tofacitinib from India, the import regulations are as follows:

The demand for Tofacitinib in importing countries is influenced by several factors:

1. Disease Prevalence: Tofacitinib is primarily used to treat rheumatoid arthritis and other autoimmune conditions. Countries with higher prevalence rates of these diseases exhibit increased demand for effective treatments. For example, the prevalence of rheumatoid arthritis in Canada is approximately 0.9%, contributing to substantial demand for Tofacitinib.

2. Government Healthcare Programs: National health initiatives that subsidize or cover the cost of medications enhance accessibility. In Malaysia, the Ministry of Health provides subsidized treatment for chronic diseases, including rheumatoid arthritis, thereby increasing the demand for medications like Tofacitinib.

3. Universal Health Coverage Expansion: Countries expanding their health coverage to include a broader population base see a rise in pharmaceutical demand. Guatemala's efforts to improve healthcare access have led to increased procurement of essential medicines.

4. WHO Essential Medicines List Procurement: Inclusion of medications in the WHO Essential Medicines List encourages countries to procure these drugs for public health programs. While Tofacitinib is not currently listed, its therapeutic class is recognized, influencing procurement decisions.

5. Tender-Based Purchasing: Many countries utilize tender systems for bulk purchasing of pharmaceuticals, ensuring cost-effectiveness and consistent supply. Iraq and Guatemala, for instance, often engage in tender-based procurement for medications, impacting the volume and frequency of Tofacitinib imports.

With 213 buyers across 67 countries, the global demand for Tofacitinib reflects a combination of disease burden, healthcare policies, and procurement strategies, presenting significant market opportunities for suppliers.